Literature DB >> 3971588

Changes in human high density lipoproteins in patients with extra-hepatic biliary obstruction.

M P Coulhon, F Tallet, J Yonger, J Agneray, D Raichvarg.   

Abstract

Plasma high density lipoproteins (HDL) from patients with obstruction of the common bile duct were studied by crossed immunoelectrophoresis and isoelectric focusing. All cholestatic HDL fractions were rich in phospholipids (51.5 +/- 9%) with high proportions of free cholesterol (13.8 +/- 1.5%). Moreover, crossed immunoelectrophoresis of sera against anti-Apo A revealed the presence of multiple immunoprecipitates sharply contrasting with the pattern formed by normal sera. Tandem crossed immunoelectrophoresis against anti-Apo A and anti-Apo B was performed with whole serum and with the HDL fraction from various cholestatic subjects. Crossed identity was observed for two of these precipitates, which could be explained by the decrease in HDL stability due to the detergent effect of bile salts. The most noteworthy changes found in cholestatic patients appeared to be the apolipoprotein pattern of HDL. Both Apo AI (48%) and Apo AII (5.5%) were greatly diminished and Apo E was present in remarkably high amounts (39%) with two additional isoforms (Apo E'1 and Apo E'2).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3971588     DOI: 10.1016/0009-8981(85)90283-9

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  Serum markers may distinguish biliary atresia from other forms of neonatal cholestasis.

Authors:  Hongtao Wang; James P Malone; Petra Erdmann Gilmore; Alan E Davis; John C Magee; R Reid Townsend; Robert O Heuckeroth
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-04       Impact factor: 2.839

2.  Diagnostic value of procalcitonin and apo-e in extrahepatic biliary atresia.

Authors:  Mandana Rafeey; Lida Saboktakin; Jamshid Shoa Hassani; Fatemeh Farahmand; Saied Aslanabadi; Amir Ghorbani-Haghjou; Sadegh Poorebrahim
Journal:  Iran J Pediatr       Date:  2014-02-18       Impact factor: 0.364

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.